Eiger BioPharmaceuticals Inc (EIGR.OQ)
EIGR.OQ on NASDAQ Stock Exchange Global Market
11.67USD
13 Dec 2018
11.67USD
13 Dec 2018
Change (% chg)
-- (--)
-- (--)
Prev Close
$11.67
$11.67
Open
--
--
Day's High
--
--
Day's Low
--
--
Volume
--
--
Avg. Vol
32,011
32,011
52-wk High
$18.00
$18.00
52-wk Low
$7.50
$7.50
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2018 | Sep '18 | 0.00 | -1.203 |
| Jun '18 | 0.00 | -0.823 | |
| Mar '18 | 0.00 | -0.839 | |
| FY 2017 | Dec '17 | 0.00 | -1.110 |
| Sep '17 | 0.00 | -1.095 | |
| Jun '17 | 0.00 | -1.332 | |
| Mar '17 | 0.00 | -1.344 | |
| FY 2016 | Dec '16 | 0.00 | -1.525 |
| Sep '16 | 0.00 | -1.492 | |
| Jun '16 | 0.00 | -1.867 | |
| Mar '16 | 0.00 | -10.418 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Dec-18 | 4 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Mar-19 | 3 | 0.00 | 0.00 | 0.00 | 0.00 |
| Year Ending Dec-18 | 4 | 0.00 | 0.00 | 0.00 | 3.33 |
| Year Ending Dec-19 | 4 | 0.00 | 0.00 | 0.00 | 7.83 |
| Earnings (per share) | |||||
| Quarter Ending Dec-18 | 4 | -0.78 | -0.71 | -0.86 | -1.20 |
| Quarter Ending Mar-19 | 3 | -0.73 | -0.67 | -0.82 | -1.27 |
| Year Ending Dec-18 | 4 | -3.62 | -3.54 | -3.74 | -4.54 |
| Year Ending Dec-19 | 4 | -3.10 | -2.86 | -3.36 | -4.68 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | -- | 69.71 | 34.39 | |
| P/E High - Last 5 Yrs. | -- | 148.17 | 46.24 | |
| P/E Low - Last 5 Yrs. | -- | 47.84 | 24.59 | |
| Beta | 2.57 | 1.08 | 0.91 | |
| Price to Sales (TTM) | -- | 49.58 | 6.22 | |
| Price to Book (MRQ) | 5.20 | 10.17 | 5.20 | |
| Price to Tangible Book (MRQ) | 5.20 | 13.83 | 6.74 | |
| Price to Cash Flow (TTM) | -- | 52.85 | 24.17 | |
| % Owned Institutions | 68.95 | 3.75 | 1.78 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | -- | 0.12 | 1.44 | |
| Dividend Yield - 5 Year Avg | -- | 0.09 | 1.46 | |
| Dividend 5 Year Growth Rate | -- | 0.79 | 4.94 | |
| Payout Ratio(TTM) | -- | 7.05 | 42.49 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | -- | 130.06 | 8.17 | |
| Sales (TTM) vs TTM 1 Yr. Ago | -- | 47.89 | 6.50 | |
| Sales - 5 Yr. Growth Rate | -- | 22.79 | 10.44 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | 28.66 | 75.90 | 23.08 | |
| EPS (TTM) vs TTM 1 Yr. Ago | 89.21 | -- | -- | |
| EPS - 5 Yr. Growth Rate | -- | 12.04 | 10.49 | |
| Capital Spending - 5 Yr. Growth Rate | -- | 9.25 | 14.59 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | -- | 2.18 | 2.28 |
| Current Ratio (MRQ) | 7.01 | 3.44 | 3.10 |
| LT Debt to Equity (MRQ) | 72.07 | 18.69 | 11.49 |
| Total Debt to Equity (MRQ) | 72.07 | 31.36 | 16.03 |
| Interest Coverage (TTM) | -30.39 | -43.32 | 30.57 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | -- | 56.37 | 54.44 | |
| Gross Margin - 5 Yr. Avg. | -- | 60.62 | 52.36 | |
| EBITD Margin (TTM) | -- | -- | -- | |
| EBITD - 5 Yr. Avg | -- | -109.98 | 13.16 | |
| Operating Margin (TTM) | -- | -185.00 | 6.07 | |
| Operating Margin - 5 Yr. Avg. | -- | -126.42 | 8.47 | |
| Pre-Tax Margin (TTM) | -- | -175.77 | 7.02 | |
| Pre-Tax Margin - 5 Yr. Avg. | -- | -132.58 | 8.71 | |
| Net Profit Margin (TTM) | -- | -182.51 | 3.12 | |
| Net Profit Margin - 5 Yr. Avg. | -- | -136.98 | 4.91 | |
| Effective Tax Rate (TTM) | -- | 21.47 | 23.26 | |
| Effective Tax Rate - 5 Yr. Avg. | -- | 15.43 | 23.83 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 0 | 7,649,006 | 873,053,182 | |
| Net Income/Employee (TTM) | -2,326,150 | 653,334 | 103,483,965 | |
| Receivable Turnover (TTM) | -- | 6.25 | 5.80 | |
| Inventory Turnover (TTM) | -- | 1.89 | 3.56 | |
| Asset Turnover (TTM) | 0.00 | 0.32 | 0.95 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | -105.46 | 6.47 | 11.45 | |
| Return on Assets - 5 Yr. Avg. | -53.65 | 5.54 | 12.50 | |
| Return on Investment (TTM) | -116.96 | 9.01 | 14.96 | |
| Return on Investment - 5 Yr. Avg. | -67.98 | 6.87 | 16.23 | |
| Return on Equity (TTM) | -143.95 | 10.15 | 16.52 | |
| Return on Equity - 5 Yr. Avg. | -- | 8.41 | 17.37 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | -- | -- | -- |
| EPS (TTM) % | 87.39 | -- | -- |
| Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Eiger BioPharmaceuticals Inc
| Period | % Actual |
% vs. S&P 500 |
Rank In Industry |
Industry Rank |
|---|---|---|---|---|
| 4 Week | 31.12 | 26.60 | 89 | 98 |
| 13 Week | 66.88 | 58.76 | 92 | 94 |
| 26 Week | 46.86 | 35.69 | 81 | 98 |
| 52 Week | -1.31 | -16.35 | 49 | 68 |
| YTD | 10.30 | -3.13 | 52 | 72 |
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
Institutional Holders
| % Shares Owned: | 74.96% |
| # of Holders: | 76 |
| Total Shares Held: | 14,313,687 |
| 3 Mo. Net Change: | 3,143,441 |
| # New Positions: | 10 |
| # Closed Positions: | 9 |
| # Increased Positions: | 36 |
| # Reduced Positions: | 19 |
| # Net Buyers: | 17 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.